Clinical trials: Heart Failure With Mid Range Ejection Fraction
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may…
- Conditions
- Heart Failure With Normal Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Heart Failure, Right Sided, Heart Failure With Mid Range Ejection Fraction
- Trial name
- PREFER-HF (NCT03480633)
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- PADN-HF-PH (NCT05824923)
- Testing
- Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy
- Trial name
- NCT05795400
- Testing
- Dapagliflozin 10mg Tab
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure With Preserved Ejection Fraction
- Trial name
- CMR for CA (NCT04862273)
- Testing
- Native T1 CMR, Web-based ATTR probability estimator (Pfizer, New York), 99mTc-DPD scintigraphy
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University of Leipzig
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction
Spironolactone in the Treatment of Heart Failure
The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of…
- Trial name
- SPIRIT-HF (NCT04727073)
- Testing
- Experimental: Spironolactone
- Where
- 69 sites in Austria, France and 3 more
- Volunteers
- 743 people
- Sponsor
- Charite University, Berlin, Germany
Heart Failure, Heart Failure With Reduced Ejection Fraction
Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study
Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
- Trial name
- MCR-HF (NCT06516562)
- Testing
- Optimal treatment
- Where
- Vietnam
- Volunteers
- 2,500 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
The Effect of Oxygen Supplementation in Training in Heart Failure Patients on Aerobic Performance and Quality of Life
Background: Physical training in patients with heart failure has been proven to reduce mortality and hospitalization rates, but many have difficulty performing an effort due to a lack of oxygen supply to the muscle and its…
- Trial name
- NCT06481657
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Laniado Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
The number of heart failure with mildly reduced or preserved ejection fraction gradually increases. SGLT2-i has been shown to reduce the risk of hospitalization for heart failure and cardiovascular death among patients with…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
- Trial name
- NCT05600387
- Testing
- Empagliflozin 10 MG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhijun Sun
Heart Failure, Heart Failure With Preserved Ejection Fraction
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Acute heart failure (AHF) is defined as rapid onset or rapid worsening of typical signs and symptoms of heart failure (HF) according to the 2016 European Society of Cardiology Guidelines.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- FUTURE-HIT (NCT05204238)
- Testing
- Transthoracic Echocardiography
- Where
- 31 sites in Australia, Belgium and 10 more
- Volunteers
- 998 people
- Sponsor
- University of Siena
Heart Failure With Mid Range Ejection Fraction
Outcome of Discharged HFmrEF Patients
This study aimed to define the independent risk factors related cardiac events (cardiac death or heart failure-related hospitalization) among heart failure with mildly reduced ejection fraction (HFmrEF) patients who discharged…
- Trial name
- OUDI-HF (NCT05240118)
- Volunteers
- 1,693 people
- Sponsor
- Xiangtan Central Hospital
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Extended IASD Investigation: REDUCE LAP-HF IV
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients…
- Trial name
- NCT04632160
- Testing
- IASD System II
- Sponsor
- Corvia Medical